The present invention generally pertains to devices for treating aneurysms. More specifically, the present invention pertains to occlusion systems for the treatment of aneurysms.
Several methods of treating aneurysms have been attempted, with varying degrees of success. For example, open craniotomy is a procedure by which an aneurysm is located, and treated, extravascularly. This type of procedure has significant disadvantages. For example, the patient undergoing open craniotomy must undergo general anesthesia. Also, the patient undergoes a great deal of trauma in the area of the aneurysm by virtue of the fact that the surgeon must sever various tissues in order to reach the aneurysm. In treating cerebral aneurysms extravascularly, for instances, the surgeon must typically remove a portion of the patient's skull, and must also traumatize brain tissue in order to reach the aneurysm.
Other techniques used in treating aneurysms are performed endovascularly. Such techniques typically involve attempting to form a mass within the sac of the aneurysm. Typically, a microcatheter is used to access the aneurysm. The distal tip of the micro catheter is placed within the sac of the aneurysm, and the microcatheter is used to inject embolic material into the sac of the aneurysm. The embolic material includes, for example, detachable coils or an embolic agent, such as a liquid polymer. The injection of these types of embolic materials suffer from disadvantages, most of which are associated with migration of the embolic material out of the aneurysm into the parent artery. This can cause permanent and irreversible occlusion of the parent artery.
For example, when detachable coils are used to occlude an aneurysm which does not have a well defined neck region, the detachable coils can migrate out of the sac of the aneurysm and into the parent artery. Further, it is, at times, difficult to gauge exactly how full the sac of the aneurysm is when detachable coils are being injected. Therefore, there is a risk of overfilling the aneurysm in which case the detachable coils also spill out into the parent artery.
Another disadvantage of detachable coils involves coil compaction over time. After filling the aneurysm, there remains space between the coils. Continued hemodynamic forces from the circulation act to compact the coil mass resulting in a cavity in the aneurysm neck. Thus, the aneurysm can recanalize.
Embolic agent migration is also a problem. For instance, where a liquid polymer is injected into the sac of the aneurysm, it can migrate out of the sac of the aneurysm due to the hemodynamics of the system. This can also lead to irreversible occlusion of the parent vessel.
Techniques have been attempted in order to deal with the disadvantages associated with embolic material migration to the parent vessel. Some such techniques, commonly referred to as flow arrest techniques, typically involve temporarily occluding the parent vessel proximal of the aneurysm, so that no blood flow occurs through the parent vessel, until a thrombotic mass has formed in the sac of the aneurysm which helps reduce the tendency of the embolic material to migrate out of the aneurysm sac. However, thrombotic mass can dissolve through normal lysis of blood. Also, in certain cases, it is highly undesirable to occlude the parent vessel even temporarily. Therefore, this technique is, at times, not available as a treatment option. In addition, even occluding the parent vessel may not prevent all embolic material migration into the parent vessel.
Another endovascular technique for treating aneurysms involves inserting a detachable balloon into the sac of the aneurysm using a microcatheter. The detachable balloon is then inflated using saline and/or contrast fluid. The balloon is then detached from the microcatheter and left within the sac of the aneurysm in an attempt to fill the sac of the aneurysm. However, detachable balloons also suffer disadvantages. For example, detachable balloons, when inflated, typically will not conform to the interior configuration of the aneurysm sac. Instead, the detachable balloon requires the aneurysm sac to conform to the exterior surface of the detachable balloon. Thus, there is an increased risk that the detachable balloon will rupture the sac of the aneurysm. Further, detachable balloons can rupture and migrate out of the aneurysm.
One embodiment of the present invention pertains to a device for at least partially occluding an aneurysm. The device includes a first elongate member having a distal end. A bridge is positioned proximate the distal end and transformable between a delivery configuration and a deployed configuration. A second elongate member is movable relative to the first elongate member, the first and second elongate members being configured such that one can be moved relative to the other in order to transform the bridge between the delivery and deployed configurations.
Another embodiment pertains to another device for at least partially occluding an aneurysm. The device comprises a first elongate member with a proximal end, a distal end and an elongated length therebetween. A clip assembly is attached proximate to the distal end of the first elongate member. The clip is moveable between a first position and a second position. The device further comprises a bridge positioned proximate to the clip assembly. The bridge is expandable between a delivery configuration, wherein the clip is in the first position, and a deployed configuration, wherein the clip is in the second position.
Another embodiment of the present invention pertains to yet another device for at least partially sealing an aneurysm. The device comprises a first elongate member having a proximal end and a distal end with an elongated length therebetween. An aneurysm neck bridge is releasably connected to the distal end of the first elongate member at a connection point. The aneurysm neck bridge has a proximal end and a distal end, and includes a first array having a deployed configuration and a delivery configuration. The first array is formed proximate the distal end of the aneurysm neck bridge. The aneurysm neck bridge further comprises a second array having a deployed configuration and a delivery configuration. The second array is formed proximate the proximal end of the aneurysm neck bridge. Yet another embodiment of the present invention pertains to a method of at least partially occluding an aneurysm having a neck. The method includes the step of providing a device to occlude the aneurysm, the device having a two array bridge having a delivery configuration and a deployed configuration. Further, the method includes inserting the device into a parent vessel, and navigating the device to the neck of the aneurysm. The method further includes deploying the first array of the bridge inside the aneurysm, and deploying the second array of the bridge outside the aneurysm. The two array bridge is detached at the connection point. The method also provides for optionally delivering coils or other material to fill the inside of the aneurysm.
Mesh portion 16 is preferably formed of braided or woven filaments or fibers which are relatively flexible. Therefore, when tubes 12 and 14 are moved relative to one another, mesh portion 16 is deployed radially outwardly relative to the tubes 12 and 14. This is illustrated by
Alternatively, device 10 can first be introduced and placed proximate neck portion 56 of aneurysm 52 and maintained in the collapsed position. Microcatheter 54 is then introduced into aneurysm 52 and device 10 is then deployed outwardly. Also, as with the embodiment described in
Of course, as with respect to device 10 shown in
It should further be noted that device 10 shown in
In one preferred embodiment, mesh portion 16 is formed of woven strands of polymer material, such as nylon, polypropylene or polyester. The polymer strands can be filled with a radiopaque material which allows the physician treating the aneurysm to fluoroscopically visualize the location of mesh portion 16 within the vasculature. Radiopaque filler materials preferably include bismuth trioxide, tungsten, titanium dioxide or barium sulfate, or radiopaque dyes such as iodine. It should also be noted that mesh portion 16 can be formed by strands of radiopaque material. The radiopaque strands allow the physician to fluoroscopically visualize the location of mesh portion 16, without the use of filled polymer materials. Such radiopaque strands may preferably be formed of gold, platinum, or a platinum/iridium alloy.
In the embodiment in which mesh portion 16 is formed of radiopaque metal strands, it is preferred to cover the strands with a polymer coating or extrusion. The coating or extrusion over the radiopaque wire strands provides fluoroscopic visualization of mesh portion 16, but also increases the resistance of the strands to bending fatigue and may also increase lubricity of the strands. The polymer coating or extrusion, in one preferred embodiment, is coated or treated with an agent which tends to resist clotting, such as heparin. Such clot resistant coatings are generally known. The polymer coating or extrusion can be any suitable extrudable polymer, or any polymer that can be applied in a thin coating, such as teflon or polyurethane.
In yet another embodiment, the strands of mesh portion 16 are formed using both metal and polymer braided strands. Combining the metal strands with the polymer strands into a braid changes the flexibility characteristics of mesh portion 16. The force required to deploy or collapse such a mesh portion is significantly reduced over that required for a mesh portion that includes only metal mesh strands. However, the radiopaque characteristics of the mesh for fluoroscopic visualization are retained. Metal strands forming such a device preferably include stainless steel, gold, platinum, platinum/iridium or nitinol. Polymer strands forming the device can preferably include nylon, polypropylene, polyester or teflon. Further, polymer strands of mesh portion 16 can be chemically modified to make them radiopaque, such as by using gold deposition onto the polymer strands, or by using ion beam plasma deposition of suitable metal ions onto the polymer strands.
Mesh portion 16 can also be formed with filaments or strands of varying diameter and/or varying flexibility. By varying the size or flexibility of the polymer strands, the flexibility characteristics of mesh portion 16, upon deployment, can also be varied. By varying the flexibility characteristics, both the deployed and collapsed configuration of mesh portion 16 can be varied or changed to substantially any desired shape. As with previous embodiments, preferred materials for the strands include nylon, polypropylene, polyester and teflon.
Not only can mesh portion 16 be formed of both polymer strands or filaments and metal strands or filaments, but it can be formed using filaments of different polymer materials. For example, different polymer materials having different flexibility characteristics can be used in forming mesh portion 16. This alters the flexibility characteristics to change the resultant configuration of mesh portion 16 in both the deployed and the collapsed positions.
Thus, device 60 can be used in a similar fashion to device 10 shown in
In addition, an inner collapsible tube portion 92 is also provided in device 84. Inner collapsible tube portion 92 is similar to outer collapsible tube portion 86, and is preferably coaxially arranged relative to outer tube portion 86. The outer tube 86 has an inner diameter which is slightly larger than the outer diameter of inner tube 92. Inner tube portion 92 also has a plurality of generally longitudinal cuts 94 formed therein to define inner struts 96. Outer collapsible tube portion 86 and inner collapsible tube portion 92 are preferably coupled to one another at their distal ends and to the distal end of inner tube 62. The proximal ends of inner and outer collapsible tube portion 86 and 92 are coupled to a distal region 74 of tube 64 and are slidable over inner tube 62.
Also, in the preferred embodiment, struts 88 are angularly offset about the outer periphery of device 84 from inner struts 96. Therefore, when device 84 is deployed, the inner struts 96 deploy outwardly within the gaps left by the deployed outer struts 88. This is better illustrated in
Devices 60 and 84 are preferably formed of any suitable material, such as PVC, polyurethane, low density polyethylene or nitinol. The design of the struts in devices 60 and 84 provide a relatively large and consistent surface area, with also relatively large amount of space between the deployed struts, when in the deployed position.
In the embodiment shown in
It should also be noted that, instead of flat strips of material, device 100 can be formed of threads or wires or other filamentous or fibrous material adhered or connected in the same manner as strips 102 and 104. As with the embodiment shown in
Further, strips 102 and 104, or the wires forming those struts, can have their distal ends angularly offset about the circumference of tubes 62 and 64 relative to their proximal ends, and adhered that way. Such a device is shown in the collapsed position in
Devices 60, 84 or 100 can also be covered with the same type of resilient material as layer 50 shown in
It should also be noted that, in accordance with the present invention, the expandable devices can be formed having different characteristics along their length. For example,
However, the distal end of device 110 also has spaces between the strips or struts 112 to allow for the escape of blood from the aneurysm upon the insertion of embolic material therein.
This same type of affect can be accomplished using strips of material having different overall configurations. For example,
Strands 142 are preferably formed of any suitable material, such as nylon, teflon, polypropylene, nitinol, or stainless steel, and outer and inner tube 62 and 64 are also preferably formed of any suitable material, and can be formed of latex or polyurethane, or other suitable materials.
In order to deploy device 150 into the radially expanded position, inner tube 62 (as shown in
In order to remove device 150 from the vasculature, inner tube 62 is again advanced distally with respect to outer tube 64 so that annular hub 156 is advanced to such a degree that surface 160 is out of engagement, and clear of, the interior surfaces 166 of expandable members 152. In this way, expandable members 152 can expand back radially inwardly with respect to tube 62 during removal of device 150 from the vasculature.
In the embodiment shown in
As discussed above, inner tube 62 and outer tube 64 can be formed of any suitable material. However, inner tube 62, when used to deliver embolic material, preferably has an inner lumen with a polytetrafluoroethylene (PTFE) inner liner to provide lubricity for wire and coil movement therethrough. The PTFE inner liner is preferably applied by dipping the tube or extruding the liner onto the tube.
In addition, in one embodiment, tubes 62 and 64 are formed of a round or flat stainless steel coil which includes a dipped or extruded polymer jacket or overcoat layer with the PTFE inner liner. The coil can also be formed of round or flat platinum or platinum/iridium, gold or other suitable material.
Also, fiber braiding can optionally be substituted for, or used in addition to, the coil wire layer. Also, the braid or the wire coils may be interspersed at various locations along the longitudinal length of the tubes. This provides variable stiffness and flexibility zones along the longitudinal length of the tubes.
In addition, any wire coils which are used in the device can have centerless ground areas so that the wires themselves have multiple diameter zones smaller than the original diameter. This tapered wire is then wound to form the coil to provide variable stiffness zones along the longitudinal length of the catheter. This same type of grinding technique can be used with square or rectangular flat metal wire to provide the same benefits.
It has been found that metal coil layers add pushability, kink resistance, increased radiopacity, and increased burst strength to a composite tube material. The use of flat wire as compared to round wire improves the pushability, kink resistance and burst strength of the catheter or tube, but may cause the tube to be less flexible. Suitable polymer jacket materials for the tubes include nylon, polyurethane and polyethylene.
Further, the tubes 62 and 64 can be formed of multiple-polymer shafts consisting of a stiffer polymer in the proximal region and a more flexible polymer in the distal region. Additionally, different combinations of metal or polymer coils or braids, and different combinations of outer and inner jackets and sheaths can be employed to obtain different flexibility segments throughout the length of the tubes, as desired. Polyfusion extrusion techniques can also be used.
It should be noted that the devices described herein can be coated with a number of suitable coatings. Among the coatings which could be applied are growth factors. A number of suitable growth factors include vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), vascular permeability growth factor (VPF), basic fibroblast growth factor (bFGF), and transforming growth factor beta (TGF-beta) Referring now to
Hypotube 201 is configured to move between at least two configurations, the first configuration being a collapsed or delivery configuration wherein the hypotube maintains its original length and circumference, as shown in
Inner tube 240 has a proximal end 242 and distal end 244. Distal end 244 comprises GDC detachment zone 250. GDC detachment zone 250 illustratively comprises desolvable material, and is provided to allow for a motion free detachment of the most distal components of elongate member 230. Distally located relative to the GDC detachment zone 250 is RO marker 222. Continuing distally along is an atramatic tip 220. Atramatic tip 220 is used to prevent damage to blood vessels when the device 230 is maneuvered through the body during a procedure to treat an aneurysm. Clip assembly 210, described in relation to
Referring to
Upon entry into neck 256, the operator deploys bridge 200 by retracting elongate member 230 through delivery tube 231 (or by extending tube 231 relative to member 230). When elongate member 230 is retracted, delivery tube 231 pushes on bridge 200 causing it to transform to the deployed configuration, and thereby causing petals 208 to span aneurysm neck 256. Without departing from the scope of the present invention, other forms of deployment may be used such as applying heat to bridge 200 to cause it to expand. As bridge 200 moves past clip 212, clip 212 engages or latches thereby preventing bridge 200 from returning back to the delivery configuration.
Following the latching of clip 212, delivery tube 231 is retracted or pulled back from clip assembly 210. This exposes both the RO marker 222 and the GDC detachment zone 250. A small electrical charge is applied to elongate member 230 or the environment that surrounds detachment zone 250, thereby causing the deterioration of GDC detachment zone 250. This results in the detachment of bridge 200 from elongate member 230 in a precise and motion free action. Elongate member 230 and tube 231 are retracted from the patient. Bridge 200, which spans the aneurysm neck 256, remains deployed within aneurysm 254.
In accordance with one aspect of the present invention coils or other material may be injected into an aneurysm 254. Such materials may be delivered at any point in the procedure, before or following deployment of bridge 200. Such materials may be deployed through inner tube 240, through delivery tube 231, or through a separate delivery tube.
Another aspect of the present invention pertains to a different type of aneurysm neck bridge.
As shown in
Bridge 300 can be used in two ways; adjunctively or as a stand-alone device to treat an aneurysm such as aneurysm 360. When bridge 300 is used adjunctively, aneurysm 360 is filled or packed with coils or other materials. Such materials can be placed in aneurysm 360 at any time, such as following the placement of first basket 302 or may be placed in aneurysm 360 following the placement of second basket 304, as shown in
When bridge 300 is used as a stand along device the use of coils is not necessary. However, coils may be utilized if desired by the treating physician. As a stand along device, second basket 304 is covered with a non-porous (elastomeric) material that prevents blood from entering the aneurysm 360 once second basket 304 is deployed across the neck 362 of aneurysm 360. However, other materials may be used that prevent blood from entering aneurysm 360. The stand alone configuration is beneficial in that it can be utilized in association with a wider variety of aneurysm configurations.
Regardless of whether bridge 330 is used ajunctively or as a stand alone device, following the placement of second basket 304, bridge 300 is detached from microcatheter 330 and tube 320. In one embodiment, a small electrical charge is provided at GDC detachment zone 350. This electrical charge causes a break down of material such that bridge 300 separates from tube 320 without having to move the microcatheter 330. However, other attachment or detachment means may be used to detach bridge 300 from tube 320. Following detachment, microcatheter 330 is removed from the parent vessel leaving bridge 300 behind.
In accordance with one embodiment, a bridge similar to bridge 300 but having only one basket or array can be utilized to treat an aneurysm. Accordingly the single basket is deployed within the aneurysm and then detached from an associated elongate delivery member. The single array is left in the aneurysm to independently at least partially occlude the neck. The single array device can be utilized adjunctively or as a stand alone device.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
This application is a continuation of, and claims priority to, U.S. patent application Ser. No. 12/489,158, filed Jun. 22, 2009, and issued as U.S. Pat. No. 9,034,054, which is a divisional of U.S. patent application Ser. No. 10/369,015, filed Feb. 19, 2003, and issued as U.S. Pat. No. 7,569,066 on Aug. 4, 2009.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
3996938 | Clark, III | Dec 1976 | A |
4416028 | Eriksson et al. | Nov 1983 | A |
4650466 | Luther | Mar 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4790819 | Li et al. | Dec 1988 | A |
4921484 | Hillstead | May 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5034001 | Garrison et al. | Jul 1991 | A |
5334210 | Gianturco | Aug 1994 | A |
5370660 | Weinstein et al. | Dec 1994 | A |
5549626 | Miller et al. | Aug 1996 | A |
5571173 | Parodi | Nov 1996 | A |
5690671 | McGurk et al. | Nov 1997 | A |
5725521 | Mueller | Mar 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5749883 | Halpern | May 1998 | A |
5795331 | Cragg et al. | Aug 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5916235 | Guglielmi | Jun 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935139 | Bates | Aug 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6059814 | Ladd | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6139564 | Teoh | Oct 2000 | A |
6168615 | Ken et al. | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6432126 | Gambale et al. | Aug 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6579303 | Amplatz | Jun 2003 | B2 |
6585748 | Jeffree | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6638257 | Amplatz | Oct 2003 | B2 |
6682546 | Amplatz | Jan 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6780196 | Chin et al. | Aug 2004 | B2 |
6802851 | Jones et al. | Oct 2004 | B2 |
6811560 | Jones et al. | Nov 2004 | B2 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7326225 | Ferrera et al. | Feb 2008 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
8034061 | Amplatz et al. | Oct 2011 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8313505 | Amplatz et al. | Nov 2012 | B2 |
8361104 | Jones et al. | Jan 2013 | B2 |
8361138 | Adams | Jan 2013 | B2 |
8398670 | Amplatz et al. | Mar 2013 | B2 |
8444668 | Jones et al. | May 2013 | B2 |
8454633 | Amplatz et al. | Jun 2013 | B2 |
8758389 | Glimsdale | Jun 2014 | B2 |
8777974 | Amplatz et al. | Jul 2014 | B2 |
8790363 | Ferrera et al. | Jul 2014 | B2 |
8821529 | Kariniemi et al. | Sep 2014 | B2 |
8864790 | Strauss et al. | Oct 2014 | B2 |
8919389 | Gries | Dec 2014 | B2 |
8940015 | Kariniemi | Jan 2015 | B2 |
8961556 | Amplatz et al. | Feb 2015 | B2 |
9039726 | Becking | May 2015 | B2 |
20030181927 | Wallace | Sep 2003 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20100023046 | Heidner et al. | Jan 2010 | A1 |
20100106235 | Kariniemi et al. | Apr 2010 | A1 |
20110144669 | Becking et al. | Jun 2011 | A1 |
20120239074 | Aboytes et al. | Sep 2012 | A1 |
20130012979 | Amplatz et al. | Jan 2013 | A1 |
20130204289 | Dasnurkar et al. | Aug 2013 | A1 |
20130253572 | Molaei et al. | Sep 2013 | A1 |
20140135810 | Divino et al. | May 2014 | A1 |
20140135828 | Amplatz et al. | May 2014 | A1 |
20140214077 | Glimsdale | Jul 2014 | A1 |
20140257357 | Ren | Sep 2014 | A1 |
20140257361 | Prom | Sep 2014 | A1 |
20140288591 | Amplatz et al. | Sep 2014 | A1 |
20150133994 | Amplatz et al. | May 2015 | A1 |
Number | Date | Country |
---|---|---|
2029280 | Nov 2000 | CA |
0664104 | Jul 1995 | EP |
2606642 | May 1988 | FR |
52111293 | Sep 1977 | JP |
833715 | Feb 1992 | JP |
4126161 | Apr 1992 | JP |
9601591 | Jan 1996 | WO |
9614027 | May 1996 | WO |
9617645 | Jun 1996 | WO |
9618343 | Jun 1996 | WO |
9701368 | Jan 1997 | WO |
9701988 | Jan 1997 | WO |
9726939 | Jul 1997 | WO |
9903404 | Jan 1999 | WO |
03011151 | Feb 2003 | WO |
Entry |
---|
Patent File History for related application U.S. Appl. No. 10/923,424 including: Notice of Allowance dated Feb. 12, 2007, for U.S. Appl. No. 10/923,424, filed Aug. 20, 2004, Inventor: Chin et al. (7 pages). Amendment Response to Final Office Action dated Oct. 12, 2006, submitted Dec. 22, 2006, for U.S. Appl. No. 10/923,424, filed Aug. 20, 2004, Inventor: Chin et al. (5 pages). |
Rejection Notice for related Japanese patent application No. 2000-501697, dispatch date May 16, 2007, including Japanese language version of Notice and associate's translation, (6 pages). |
Final Rejection Notice for related Japanese patent application No. 2000-51697, dispatch date Dec. 26, 2007, including associate's translation only (3 pages). |
EPO Communication pursuant to Article 96(2) EPC, dated Dec. 30, 2003, for EP application No. 98933190.5, Applicant Scimed Life Systems (5 pages). |
Response to EPO Communication dated Dec. 30, 2003, submitted on Apr. 20, 2004, for EP application No. 98933190.5, Applicant Scimed Life Systems (11 pages). |
EPO Communication pursuant to Article 96(2) EPC, dated May 26, 2004 for EP application No. 98933190.5, Applicant Scimed Life Systems (2 pages). |
Response to EPO Communication dated May 26, 2004, submitted on Aug. 11, 2004, for EP application No. 98933190.5, Applicant Scimed Life Systems (4 pages). |
EPO Communication pursuant to Article 96(2) EPC, dated Apr. 8, 2005 for EP application No. 98933190.5, Applicant Scimed Life Systems (5 pages). |
Response to EPO Communication dated Apr. 8, 2005, submitted on Oct. 11, 2005, for EP application No. 98933190.5, Applicant Scimed Life Systems (5 pages). |
EPO Communication pursuant to Article 96(2) EPC, dated Nov. 8, 2006 for EP application No. 98933190.5, Applicant Scimed Life Systems (3 pages). |
Response to EPO Communication dated Nov. 8, 2005, submitted on Mar. 6, 2007, for EP application No. 98933190.5, Applicant Scimed Life Systems (6 pages). |
Invitation to Pay Fees and Partial International Search Report for PCT/US2004/004944, Applicant Scimed Life Systems, Inc., Form PCT/ISA/206, dated Aug. 2, 2004 (5 pages). |
Prosecution history for U.S. Appl. No. 13/230,628, filed Sep. 12, 2011, including (149 pages total): Non-final rejection dated Jul. 18, 2013; Amendment response dated Sep. 12, 2013; Final Rejection dated Dec. 18, 2013; Amendment submitted/entered with filing of CPA/RCE dated Feb. 3, 2014. |
Number | Date | Country | |
---|---|---|---|
20150164512 A1 | Jun 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10369015 | Feb 2003 | US |
Child | 12489158 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12489158 | Jun 2009 | US |
Child | 14632942 | US |